Conatus and Novartis suffer another midphase NASH flop

Conatus and Novartis suffer another midphase NASH flop

Source: 
Fierce Biotech
snippet: 

Conatus Pharmaceuticals’ emricasan has failed another midphase clinical trial. The latest setback saw the Novartis-partnered liver disease drug fail to beat placebo in NASH patients, wiping another 50% off Conatus’ stock price.